Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04126486 · ClinicalTrials.gov registry record · Phase 4
A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke
A Phase 4 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 4
- Development phase
- 11,931
- Enrollment target
NCT04126486 is a Phase 4 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 11,931 participants.
The verdict
NCT04126486, a Phase 4 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11,931 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if an AF detection intervention in men and women at least 70 years of age with undiagnosed atrial fibrillation (AF) or atrial flutter (AFL) reduces the person-years incidence rate of stroke compared to usual care (no AF detection intervention).
Interventions
- OTHER Zio®XT Monitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,931 participants |
| Start Date | 2019-12-17 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04126486
The ClinicalTrials.gov registry entry for NCT04126486 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 11,931 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zio®XT Monitor is the first listed.
NCT04126486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04126486 about?
NCT04126486 is a clinical study titled "A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke". The purpose of this study is to determine if an AF detection intervention in men and women at least 70 years of age with undiagnosed atrial fibrillation (AF) or atrial flutter (AFL) reduces the person-years incidence rate of stroke compared to usual care (no AF detection intervention).
What is the current status of trial NCT04126486?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11,931 participants. The study started on 2019-12-17. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT04126486?
The interventions under investigation include: Zio®XT Monitor (OTHER).
Who is sponsoring clinical trial NCT04126486?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.